1. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, Yuen K, Lee J, Giamoutsous P, Olver JN, Zalcberg J, Ball D, Bull C, Fox R (1987) Carboplatin (CBDCA, JM8) and VP 16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 5: 1574?1578
2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies withcis-diammine-1,1-cyclobutane dicarboxylate platinum (II). Cancer Chemother Pharmacol 9: 140?147
3. Curt GA, Grygiel JJ, Corden BJ (1983) A phase I and pharmacokinetic study of diammine cyclobutane-dicarboxylate platinum (NSC 241240). Cancer Res 43: 4470?4473
4. Dombernowsky P, Sorensen S, Aisner J, Hansen HH (1979)cis-Dichlorodiammineplatinum(II) in small cell anaplastic bronchogenic carcinoma: a phase II study. Cancer Treat Rep 63: 543?545
5. EORTC Lung Cancer Cooperative Group (1988) Evaluation of non-cross resistance of carboplatin-containing regimens with cyclophosphamide, doxorubicin and etoposide in patients with small cell lung cancer. EORTC study 08862, abstract 6. 1. 63, Interlaken